Sutro Biopharma (STRO) Interest Expenses (2016 - 2026)
Sutro Biopharma (STRO) posted Interest Expenses of -$7.1 million for Q4 2025, down 136.03% sequentially from $19.7 million in Q3 2025, and down 2974.49% YoY from $247000.0 in Q4 2024.
Sutro Biopharma (STRO) Interest Expenses (2016 - 2026) Analysis & Trends
Sutro Biopharma has reported Interest Expenses for 10 years, with the latest figure at -$7.1 million in Q4 2025.
- Quarterly Interest Expenses fell 2974.49% year-over-year to -$7.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.3 million (down 30.46% YoY) and the FY2025 annual result came in at $272.2 million, up 19.47% from the prior year.
- Interest Expenses eased to -$7.1 million in Q4 2025 per STRO's latest filing, from $19.7 million in the prior quarter.
- Over five years, Interest Expenses peaked at $40.6 million in Q2 2023 and troughed at -$7.1 million in Q4 2025.
- A 5-year average of $8.7 million and a median of $2.3 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses surged 6660.83% in 2023, then plunged 2974.49% in 2025.
- Over 5 years, Interest Expenses stood at $3.7 million in 2021, then sank by 88.38% to $427000.0 in 2022, then tumbled by 1171.19% to -$4.6 million in 2023, then jumped by 105.4% to $247000.0 in 2024, then slumped by 2974.49% to -$7.1 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered -$7.1 million, $19.7 million, and $22.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | 11.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.68 Mn |
| Jun 30, 2026 | 11.68 Mn |
| Dec 31, 2025 | -7.10 Mn |
| Dec 31, 2025 | -7.10 Mn |
| Sep 30, 2025 | 19.71 Mn |
| Sep 30, 2025 | 19.71 Mn |
| Jun 30, 2025 | 22.13 Mn |
| Jun 30, 2025 | 22.13 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 247,000.00 |
| Dec 31, 2024 | 247,000.00 |
| Sep 30, 2024 | 8.29 Mn |
| Sep 30, 2024 | 8.29 Mn |
| Jun 30, 2024 | 8.29 Mn |
| Jun 30, 2024 | 8.29 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Dec 31, 2023 | -4.57 Mn |
| Dec 31, 2023 | -4.57 Mn |